Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Among authors: zoppegno l. Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1. Epub 2009 Sep 18. Lancet. 2009. PMID: 19767089 Free article. Clinical Trial.
Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S, Corrado C, Pavlovsky MA, Prates MV, Zoppegno L, Giunta M, Cerutti I, Palomino E, Pagani F, Lastiri F, Bar D, Bezares RF, Avila G. Pavlovsky S, et al. Among authors: zoppegno l. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):181-5. doi: 10.3816/CLML.2010.n.028. Clin Lymphoma Myeloma Leuk. 2010. PMID: 20511162 Clinical Trial.
T-cell lymphomas in South america and europe.
Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, de Souza CA, Gabús R, Zoppegno L, Zoppegno L, Milone J, Pavlovsky A, Connors JM, Foss FM, Horwitz SM, Liang R, Montoto S, Pileri SA, Polliack A, Vose JM, Zinzani PL, Zucca E, Federico M. Bellei M, et al. Among authors: zoppegno l. Rev Bras Hematol Hemoter. 2012;34(1):42-7. doi: 10.5581/1516-8484.20120013. Rev Bras Hematol Hemoter. 2012. PMID: 23049383 Free PMC article.
PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
Pavlovsky A, Fernandez I, Kurgansky N, Prates V, Zoppegno L, Negri P, Milone G, Cerutti I, Zabaljauregui S, Mariano R, Grecco HF, Basquiera AL, Saba S, Rudoy S, Sackmann F, Castano V, Remaggi G, Cabrejo M, Roveri E, Casale MF, Cabane V, Taus R, Venturini C, Sakamoto F, Varela AI, Riddick M, Pavlovsky S; Grupo Argentino de tratamiento de Leucemia Aguda (GATLA), Argentina. Pavlovsky A, et al. Among authors: zoppegno l. Br J Haematol. 2019 Jun;185(5):865-873. doi: 10.1111/bjh.15838. Epub 2019 Mar 12. Br J Haematol. 2019. PMID: 30864146 Free article.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Coiffier B, et al. Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1. Lancet Oncol. 2011. PMID: 21724462 Clinical Trial.